Idrugs
-
The 12th International AEK Cancer Congress was attended by approximately 500 oncologists, basic scientists and biotechnologists. The majority of the oral contributions were dedicated to the molecular mechanisms of oncogenesis and potential targets for cancer treatment; novel drugs and approaches for cancer therapy were presented in one of seven sessions, as well as in a series of posters. Antisense oligonucleotides, peptide aptamers and siRNA technology were disclosed at the meeting as novel approaches for cancer treatment. In addition, a number of anticancer drugs were discussed, including 17-allylamino demethoxygeldanamycin (17-AAG), treosulfan, sulfasalazine and U-0126, and also the receptor ligand TRAIL.
-
The Spanish National Cancer Center has launched a new series of cancer conferences devoted to timely themes in oncology. These meetings aim to bring together a maximum of 50 participants, including 20 to 25 speakers along with 25 to 30 participants for in-depth discussion of new results and ideas in frontline cancer research. There is no registration fee to attend, but participants must organize their own travel and accommodation expenses; free communications are presented as posters, but a few may be selected for short (15 min) oral presentations. This particular meeting was organized by Amancio Carnero and David H Beach, and was mostly devoted to state of the art methodologies for the identification of new targets for anticancer drug design, although the development of novel drugs was also discussed.